The IRA may alter the incentives drug firms have to pursue evergreening strategies, as having generic or biosimilar competition can exempt a drug from price negotiation.
Inflation Reduction Act May Accelerate Generic And Biosimilar Market Entry, But Questions Remain Around CMS Guidance
